Tapewire

Nasdaq · USD

IBIO

iBio, Inc.

Export transactions ↓
Tapewire entity
6906
SEC CIK
0001420720
Parsed reports
157

Last 12 months

Inside the activity.

4 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202640
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
October 14, 2026 Filed Oct 15, 2026 22:33 UTC GrantStock Option (right to buy) · Derivative 38,000 $0.00 Strike: $0.78 $0.00
Disclosure

SEC source: 0001104659-26-116321 · tm2627695-5_4seq1.xml · derivative · entry 1

Kropotova Alexandra · CIK 0001825323 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,000

Underlying: Common Stock · 38,000 shares

Expires 2036-10-13

F1 · security: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

F1 · shares: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

F1 · derivative.exercise_date: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

Read SEC document
October 14, 2026 Filed Oct 15, 2026 22:34 UTC GrantStock Option (right to buy) · Derivative 38,000 $0.00 Strike: $0.78 $0.00
Disclosure

SEC source: 0001104659-26-116322 · tm2627695-6_4seq1.xml · derivative · entry 1

Stoner Elizabeth · CIK 0001415739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,000

Underlying: Common Stock · 38,000 shares

Expires 2036-10-13

F1 · security: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

F1 · shares: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

F1 · derivative.exercise_date: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:01 UTC
Carr MollyChief Medical Officer
GrantStock Option (right to buy) · Derivative 430,000 $0.00 Strike: $1.40 $0.00
Disclosure

SEC source: 0001104659-26-090344 · tm2621854-2_4seq1.xml · derivative · entry 1

Carr Molly · CIK 0002147544 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 430,000

Underlying: Common Stock · 430,000 shares

Expires 2036-07-30

F1 · security: Stock option granted as an inducement award to the Reporting Person that was granted outside of the iBio, Inc. 2023 Omnibus Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) on July 31, 2026 (the "Grant Date").

F2 · derivative.exercise_date: Vesting 25% on the one-year anniversary of the Grant Date, with an additional 6.25% vesting every three months thereafter, provided the Reporting Person remains employed by iBio, Inc. through each applicable vesting date.

Read SEC document
May 18, 2026 Filed May 19, 2026 11:44 UTC GrantStock Option (right to buy) · Derivative 60,000 $0.00 Strike: $1.42 $0.00
Disclosure

SEC source: 0001104659-26-063503 · tm2615041-1_4seq1.xml · derivative · entry 1

Stoner Elizabeth · CIK 0001415739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2036-05-17

F1 · derivative.exercise_date: Vesting monthly on a pro rata basis over 36 months.

Read SEC document
March 26, 2026 Filed Mar 27, 2026 16:05 UTC
Banjak MarcChief Legal Officer
PurchaseCommon Stock 1,434 $1.76 $2,523.84
Disclosure

SEC source: 0001104659-26-036093 · tm269997-1_4seq1.xml · nonDerivative · entry 2

Banjak Marc · CIK 0002033869 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Read SEC document
March 26, 2026 Filed Mar 27, 2026 16:05 UTC
Banjak MarcChief Legal Officer
PurchaseCommon Stock 12,500 $1.64 $20,531.25
Disclosure

SEC source: 0001104659-26-036093 · tm269997-1_4seq1.xml · nonDerivative · entry 1

Banjak Marc · CIK 0002033869 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,566

Read SEC document
March 19, 2026 Filed Mar 23, 2026 11:31 UTC
Duran FelipeChief Financial Officer
PurchaseCommon Stock 24,835 $2.02 $50,131.93
Disclosure

SEC source: 0001104659-26-033028 · tm269462-2_4seq1.xml · nonDerivative · entry 1

Duran Felipe · CIK 0001964267 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,974

F1 · price: Represents shares of the Issuer's common stock purchased by the Reporting Person in multiple transactions at prices ranging from $2.01 through $2.02, inclusive, having a weighted average price as shown in column 4 of $2.0186. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 11:30 UTC
Brenner MartinDirector · See Remarks
PurchaseCommon Stock 12,336 $2.02 $24,918.72
Disclosure

SEC source: 0001104659-26-033021 · tm269462-1_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,652

Read SEC document
January 28, 2026 Filed Jan 30, 2026 06:16 UTC
Banjak MarcChief Legal Officer
GrantStock Option (right to buy) · Derivative 146,000 $0.00 Strike: $2.23 $0.00
Disclosure

SEC source: 0001104659-26-008266 · tm264470-3_4seq1.xml · derivative · entry 1

Banjak Marc · CIK 0002033869 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,000

Underlying: Common Stock · 146,000 shares

Expires 2036-01-27

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

Read SEC document
January 28, 2026 Filed Jan 30, 2026 11:15 UTC
Duran FelipeChief Financial Officer
GrantStock Option (right to buy) · Derivative 179,000 $0.00 Strike: $2.23 $0.00
Disclosure

SEC source: 0001104659-26-008265 · tm264470-2_4seq1.xml · derivative · entry 1

Duran Felipe · CIK 0001964267 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,000

Underlying: Common Stock · 179,000 shares

Expires 2036-01-27

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

Read SEC document
January 28, 2026 Filed Jan 30, 2026 11:15 UTC
Brenner MartinDirector · See Remarks
GrantStock Option (right to buy) · Derivative 479,000 $0.00 Strike: $2.23 $0.00
Disclosure

SEC source: 0001104659-26-008262 · tm264470-1_4seq1.xml · derivative · entry 1

Brenner Martin · CIK 0001770235 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 479,000

Underlying: Common Stock · 479,000 shares

Expires 2036-01-27

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

Read SEC document
November 20, 2025 Filed Nov 24, 2025 16:06 UTC GrantStock Option (right to buy) · Derivative 13,500 $0.00 Strike: $1.00 $0.00
Disclosure

SEC source: 0001104659-25-115408 · tm2532045-2_4seq1.xml · derivative · entry 1

Parada Antonio Bernardino Guimaraes · CIK 0002047863 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2035-11-19

F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

Read SEC document
November 20, 2025 Filed Nov 24, 2025 21:10 UTC GrantStock Option (right to buy) · Derivative 13,500 $0.00 Strike: $1.00 $0.00
Disclosure

SEC source: 0001104659-25-115414 · tm2532045-6_4seq1.xml · derivative · entry 1

Schimmelpennink Evert B. · CIK 0001713795 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2035-11-19

F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

Read SEC document
November 20, 2025 Filed Nov 24, 2025 21:09 UTC GrantStock Option (right to buy) · Derivative 13,500 $0.00 Strike: $1.00 $0.00
Disclosure

SEC source: 0001104659-25-115411 · tm2532045-5_4seq1.xml · derivative · entry 1

Clark William D · CIK 0001355415 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2035-11-19

F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

Read SEC document
November 20, 2025 Filed Nov 24, 2025 21:08 UTC
Sender GaryDirector
GrantStock Option (right to buy) · Derivative 13,500 $0.00 Strike: $1.00 $0.00
Disclosure

SEC source: 0001104659-25-115410 · tm2532045-4_4seq1.xml · derivative · entry 1

Sender Gary · CIK 0001659085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2035-11-19

F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

Read SEC document
November 20, 2025 Filed Nov 24, 2025 21:07 UTC GrantStock Option (right to buy) · Derivative 13,500 $0.00 Strike: $1.00 $0.00
Disclosure

SEC source: 0001104659-25-115409 · tm2532045-3_4seq1.xml · derivative · entry 1

Kropotova Alexandra · CIK 0001825323 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2035-11-19

F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

Read SEC document
November 20, 2025 Filed Nov 24, 2025 21:05 UTC GrantStock Option (right to buy) · Derivative 13,500 $0.00 Strike: $1.00 $0.00
Disclosure

SEC source: 0001104659-25-115407 · tm2532045-1_4seq1.xml · derivative · entry 1

Arkowitz David · CIK 0001296999 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2035-11-19

F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

Read SEC document
October 20, 2025 Filed Oct 22, 2025 18:28 UTC
Banjak MarcChief Legal Officer
GrantStock Option (right to buy) · Derivative 55,000 $0.00 Strike: $0.89 $0.00
Disclosure

SEC source: 0001104659-25-101608 · tm2529309-2_4seq1.xml · derivative · entry 1

Banjak Marc · CIK 0002033869 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-10-19

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

Read SEC document
October 20, 2025 Filed Oct 22, 2025 22:29 UTC
Duran FelipeChief Financial Officer
GrantStock Option (right to buy) · Derivative 75,000 $0.00 Strike: $0.89 $0.00
Disclosure

SEC source: 0001104659-25-101609 · tm2529309-3_4seq1.xml · derivative · entry 1

Duran Felipe · CIK 0001964267 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2035-10-19

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

Read SEC document
October 20, 2025 Filed Oct 22, 2025 22:27 UTC
Brenner MartinDirector · See Remarks
GrantStock Option (right to buy) · Derivative 180,000 $0.00 Strike: $0.89 $0.00
Disclosure

SEC source: 0001104659-25-101607 · tm2529309-1_4seq1.xml · derivative · entry 1

Brenner Martin · CIK 0001770235 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2035-10-19

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

Read SEC document
February 21, 2025 Filed Feb 24, 2025 06:01 UTC
Banjak MarcChief Legal Officer
GrantStock Option (right to buy) · Derivative 71,000 $0.00 Strike: $3.48 $0.00
Disclosure

SEC source: 0001104659-25-016311 · tm257339-3_4seq1.xml · derivative · entry 1

Banjak Marc · CIK 0002033869 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,000

Underlying: Common Stock · 71,000 shares

Expires 2035-02-20

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

Read SEC document
February 21, 2025 Filed Feb 24, 2025 11:00 UTC
Duran FelipeChief Financial Officer
GrantStock Option (right to buy) · Derivative 84,700 $0.00 Strike: $3.48 $0.00
Disclosure

SEC source: 0001104659-25-016307 · tm257339-2_4seq1.xml · derivative · entry 1

Duran Felipe · CIK 0001964267 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,700

Underlying: Common Stock · 84,700 shares

Expires 2035-02-20

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

Read SEC document
February 21, 2025 Filed Feb 24, 2025 11:00 UTC
Brenner MartinDirector · See Remarks
GrantStock Option (right to buy) · Derivative 230,700 $0.00 Strike: $3.48 $0.00
Disclosure

SEC source: 0001104659-25-016298 · tm257339-1_4seq1.xml · derivative · entry 1

Brenner Martin · CIK 0001770235 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 230,700

Underlying: Common Stock · 230,700 shares

Expires 2035-02-20

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

Read SEC document
January 10, 2025 Filed Jan 13, 2025 16:30 UTC PurchaseCommon Stock 183,823 $2.72 $499,998.56
Disclosure

SEC source: 0001104659-25-003059 · tm253156-2_4seq1.xml · nonDerivative · entry 1

Parada Antonio Bernardino Guimaraes · CIK 0002047863 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 183,823

F1 · kind: Shares purchased by MagicRoad SGPS, Unipessoal LDA, of which the Reporting Person is the sole director and shareholder, pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025.

F2 · ownership.direct: The reported securities are held directly by MagicRoad SGPS, Unipessoal LDA ("MagicRoad"). The Reporting Person is the sole director and shareholder of MagicRoad and has sole voting and investment power of MagicRoad with respect to the shares held by MagicRoad.

Read SEC document
January 10, 2025 Filed Jan 13, 2025 16:33 UTC
Banjak MarcChief Legal Officer
PurchaseCommon Stock 9,191 $2.72 $24,999.52
Disclosure

SEC source: 0001104659-25-003062 · tm253156-5_4seq1.xml · nonDerivative · entry 1

Banjak Marc · CIK 0002033869 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,066

F1 · kind: Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025.

Read SEC document
January 10, 2025 Filed Jan 13, 2025 21:34 UTC
Duran FelipeChief Financial Officer
PurchaseCommon Stock 9,191 $2.72 $24,999.52
Disclosure

SEC source: 0001104659-25-003064 · tm253156-7_4seq1.xml · nonDerivative · entry 1

Duran Felipe · CIK 0001964267 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,139

F1 · kind: Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025.

Read SEC document
January 10, 2025 Filed Jan 13, 2025 21:34 UTC
Brenner MartinDirector · See Remarks
PurchaseCommon Stock 9,191 $2.72 $24,999.52
Disclosure

SEC source: 0001104659-25-003063 · tm253156-6_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,316

F1 · kind: Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025.

Read SEC document
January 10, 2025 Filed Jan 13, 2025 21:32 UTC PurchaseCommon Stock 18,382 $2.72 $49,999.04
Disclosure

SEC source: 0001104659-25-003061 · tm253156-4_4seq1.xml · nonDerivative · entry 1

Arkowitz David · CIK 0001296999 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,382

F1 · kind: Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025.

Read SEC document
January 10, 2025 Filed Jan 13, 2025 21:31 UTC PurchaseCommon Stock 1,838 $2.72 $4,999.36
Disclosure

SEC source: 0001104659-25-003060 · tm253156-3_4seq1.xml · nonDerivative · entry 1

Clark William D · CIK 0001355415 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,838

F1 · kind: Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025.

Read SEC document
January 10, 2025 Filed Jan 13, 2025 21:30 UTC
Sender GaryDirector
PurchaseCommon Stock 9,191 $2.72 $24,999.52
Disclosure

SEC source: 0001104659-25-003058 · tm253156-1_4seq1.xml · nonDerivative · entry 1

Sender Gary · CIK 0001659085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,191

F1 · kind: Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025.

Read SEC document
November 21, 2024 Filed Nov 25, 2024 21:34 UTC
Sender GaryDirector
GrantStock Option (right to buy) · Derivative 18,900 $0.00 Strike: $2.45 $0.00
Disclosure

SEC source: 0001104659-24-122595 · tm2429436-6_4seq1.xml · derivative · entry 1

Sender Gary · CIK 0001659085 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,900

Underlying: Common Stock · 18,900 shares

Expires 2034-11-20

F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

Read SEC document
November 21, 2024 Filed Nov 25, 2024 21:33 UTC GrantStock Option (right to buy) · Derivative 18,900 $0.00 Strike: $2.45 $0.00
Disclosure

SEC source: 0001104659-24-122593 · tm2429436-5_4seq1.xml · derivative · entry 1

Schimmelpennink Evert B. · CIK 0001713795 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,900

Underlying: Common Stock · 18,900 shares

Expires 2034-11-20

F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

Read SEC document
November 21, 2024 Filed Nov 25, 2024 21:32 UTC GrantStock Option (right to buy) · Derivative 18,900 $0.00 Strike: $2.45 $0.00
Disclosure

SEC source: 0001104659-24-122592 · tm2429436-4_4seq1.xml · derivative · entry 1

Kropotova Alexandra · CIK 0001825323 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,900

Underlying: Common Stock · 18,900 shares

Expires 2034-11-20

F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

Read SEC document
November 21, 2024 Filed Nov 25, 2024 21:32 UTC GrantStock Option (right to buy) · Derivative 18,900 $0.00 Strike: $2.45 $0.00
Disclosure

SEC source: 0001104659-24-122590 · tm2429436-3_4seq1.xml · derivative · entry 1

Clark William D · CIK 0001355415 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,900

Underlying: Common Stock · 18,900 shares

Expires 2034-11-20

F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

Read SEC document
November 21, 2024 Filed Nov 25, 2024 21:31 UTC GrantStock Option (right to buy) · Derivative 12,600 $0.00 Strike: $2.45 $0.00
Disclosure

SEC source: 0001104659-24-122589 · tm2429436-2_4seq1.xml · derivative · entry 1

Arkowitz David · CIK 0001296999 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,600

Underlying: Common Stock · 12,600 shares

Expires 2034-11-20

F1 · security: These options vest pro rata on a monthly basis over three years commencing on the date of the grant.

F1 · shares: These options vest pro rata on a monthly basis over three years commencing on the date of the grant.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over three years commencing on the date of the grant.

Read SEC document
November 21, 2024 Filed Dec 9, 2024 17:07 UTC GrantStock Option (right to buy) · Derivative 12,600 $0.00 Strike: $2.45 $0.00
Disclosure

SEC source: 0001104659-24-126813 · tm2430052-2_4seq1.xml · derivative · entry 1

Parada Antonio Bernardino Guimaraes · CIK 0002047863 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,600

Underlying: Common Stock · 12,600 shares

Expires 2034-11-20

F1 · security: These options vest pro rata on a monthly basis over three years commencing on the date of the grant.

F1 · shares: These options vest pro rata on a monthly basis over three years commencing on the date of the grant.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over three years commencing on the date of the grant.

Read SEC document
May 09, 2024 Filed May 13, 2024 20:32 UTC
Brenner MartinSee Remarks
GrantStock Option (right to buy) · Derivative 110,000 $0.00 Strike: $1.88 $0.00
Disclosure

SEC source: 0001104659-24-060594 · tm2414241-2_4seq1.xml · derivative · entry 2

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2034-05-09

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

F2 · derivative.exercise_date: These options vest in equal amounts on a quarterly basis over a 36-month period commencing on the date of grant.

Read SEC document
May 09, 2024 Filed May 13, 2024 20:32 UTC
Brenner MartinSee Remarks
GrantStock Option (right to buy) · Derivative 147,300 $0.00 Strike: $1.88 $0.00
Disclosure

SEC source: 0001104659-24-060594 · tm2414241-2_4seq1.xml · derivative · entry 1

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,300

Underlying: Common Stock · 147,300 shares

Expires 2034-05-09

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

Read SEC document
May 09, 2024 Filed May 13, 2024 20:30 UTC
Duran FelipeChief Financial Officer
GrantStock Option (right to buy) · Derivative 90,000 $0.00 Strike: $1.88 $0.00
Disclosure

SEC source: 0001104659-24-060588 · tm2414241-1_4seq1.xml · derivative · entry 1

Duran Felipe · CIK 0001964267 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2034-05-09

F1 · security: These options vest in equal amounts on a quarterly basis over a 36-month period commencing on the date of grant.

F1 · derivative.exercise_date: These options vest in equal amounts on a quarterly basis over a 36-month period commencing on the date of grant.

Read SEC document
April 25, 2024 Filed Apr 26, 2024 21:02 UTC
Duran FelipeChief Financial Officer
GrantStock Option (right to buy) · Derivative 35,800 $0.00 Strike: $1.72 $0.00
Disclosure

SEC source: 0001104659-24-053070 · tm2412866-1_4seq1.xml · derivative · entry 1

Duran Felipe · CIK 0001964267 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,800

Underlying: Common Stock · 35,800 shares

Expires 2034-04-25

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

Read SEC document
November 01, 2023 Filed Nov 3, 2023 20:01 UTC
Brenner MartinSee Remarks
SaleCommon Stock 4,881 $0.27 $1,295.91
Disclosure

SEC source: 0001104659-23-114269 · tm2329795d1_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182,502

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F2 · balance_after: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2654 to $0.2671 inclusive. The Reporting Person undertakes to provide to the Issuer, any securities holder of the Issuer, or the staff of the Securities and Exchange Commission, upon report, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
October 03, 2023 Filed Oct 5, 2023 20:01 UTC
Brenner MartinSee Remarks
SaleCommon Stock 5,267 $0.30 $1,591.69
Disclosure

SEC source: 0001104659-23-107157 · tm2327750-1_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,383

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

Read SEC document
October 02, 2023 Filed Oct 3, 2023 20:01 UTC
Brenner MartinSee Remarks
SaleCommon Stock 4,215 $0.31 $1,310.87
Disclosure

SEC source: 0001104659-23-106379 · tm2327541-1_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 192,650

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3100 to $0.3129 inclusive. The Reporting Person undertakes to provide to the Issuer, any securities holder of the Issuer, or the staff of the Securities and Exchange Commission, upon report, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 28, 2023 Filed Aug 30, 2023 20:22 UTC
Brenner MartinSee Remarks
SaleCommon Stock 5,011 $0.31 $1,528.86
Disclosure

SEC source: 0001104659-23-096877 · tm2325166-1_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,865

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3051 to $0.3068 inclusive. The Reporting Person undertakes to provide to the Issuer, any securities holder of the Issuer, or the staff of the Securities and Exchange Commission, upon report, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 23, 2023 Filed Aug 24, 2023 20:02 UTC
Brenner MartinSee Remarks
GrantStock Option (right to buy) · Derivative 120,000 $0.00 Strike: $0.35 $0.00
Disclosure

SEC source: 0001104659-23-094884 · tm2324750-1_4seq1.xml · derivative · entry 1

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2033-08-23

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

Read SEC document
August 23, 2023 Filed Aug 24, 2023 20:03 UTC
Duran FelipeChief Financial Officer
GrantStock Option (right to buy) · Derivative 60,000 $0.00 Strike: $0.35 $0.00
Disclosure

SEC source: 0001104659-23-094885 · tm2324750-2_4seq1.xml · derivative · entry 1

Duran Felipe · CIK 0001964267 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2033-08-23

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

Read SEC document
July 27, 2023 Filed Jul 28, 2023 20:01 UTC
Brenner MartinSee Remarks
SaleCommon Stock 35 $0.51 $17.85
Disclosure

SEC source: 0001104659-23-085306 · tm2322333-1_4seq1.xml · nonDerivative · entry 2

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 201,876

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

Read SEC document
July 27, 2023 Filed Jul 28, 2023 20:01 UTC
Brenner MartinSee Remarks
SaleCommon Stock 4,480 $0.51 $2,289.73
Disclosure

SEC source: 0001104659-23-085306 · tm2322333-1_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 201,911

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

Read SEC document
July 12, 2023 Filed Jul 13, 2023 20:02 UTC
Brenner MartinSee Remarks
SaleCommon Stock 47,020 $0.59 $27,520.81
Disclosure

SEC source: 0001104659-23-080733 · tm2321232-1_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,391

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

Read SEC document
June 26, 2023 Filed Jun 27, 2023 12:12 UTC
Brenner MartinSee Remarks
GrantCommon Stock 75,833 $0.00 $0.00
Disclosure

SEC source: 0001104659-23-075015 · tm2319771-1_4seq1.xml · nonDerivative · entry 2

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 253,411

F2 · kind: Consists of 75,833 shares of the Company's common stock, represented by 75,833 RSUs granted under the Company's 2020 Plan. Each RSU represents a contingent right to receive one share of Common Stock. The 75,833 RSUs vest pro rata over a seven-month period, such vesting to terminate if Dr. Brenner is no longer the Company's Chief Executive Officer

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.